Patents by Inventor Iain C. A. F. Robinson

Iain C. A. F. Robinson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating cartilage disorders
    Patent number: 8110548
    Abstract: The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor.
    Type: Grant
    Filed: November 2, 2007
    Date of Patent: February 7, 2012
    Assignee: Genentech, Inc.
    Inventors: Yvonne Man-Yee Chen, Ross G. Clark, Andrea G. Cochran, Yves Dubaquie, Paul J. Fielder, Ellen Filvaroff, Henry B. Lowman, Deborah L. Mortensen, Iain C. A. F. Robinson, Nicholas J. Skelton
  • Article of manufacture
    Patent number: 7947650
    Abstract: The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: May 24, 2011
    Assignee: Genentech, Inc.
    Inventors: Yvonne Man-Yee Chen, Ross G. Clark, Andrea G. Cochran, Yves Dubaquie, Paul J. Fielder, Ellen Filvaroff, Henry B. Lowman, Deborah L. Mortensen, Iain C. A. F. Robinson, Nicholas J. Skelton
  • METHOD FOR TREATING CARTILAGE DISORDERS
    Publication number: 20100130411
    Abstract: The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor.
    Type: Application
    Filed: November 2, 2007
    Publication date: May 27, 2010
    Inventors: Yvonne Man-Yee Chen, Ross G. Clark, Andrea G. Cochran, Yves Dubaquie, Paul J. Fielder, Ellen Filvaroff, Henry B. Lowman, Deborah L. Mortensen, Iain C.A.F. Robinson, Nicholas J. Skelton
  • METHOD FOR TREATING CARTILAGE DISORDERS
    Publication number: 20090011988
    Abstract: The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor.
    Type: Application
    Filed: October 30, 2007
    Publication date: January 8, 2009
    Inventors: Yvonne Man-Yee Chen, Ross G. Clark, Andrea G. Cochran, Yves Dubaquie, Paul J. Fielder, Ellen Filvaroff, Henry B. Lowman, Deborah L. Mortensen, Iain C.A.F. Robinson, Nicholas J. Skelton
  • Method for treating cartilage disorders
    Patent number: 7423017
    Abstract: The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: September 9, 2008
    Assignee: Genentech, Inc.
    Inventors: Yvonne Man-Yee Chen, Ross G. Clark, Andrea G. Cochran, Yves Dubaquie, Paul J. Fielder, Ellen Filvaroff, Henry B. Lowman, Deborah L. Mortensen, Iain C. A. F. Robinson, Nicholas J. Skelton
  • Insulin-like growth factor agonist molecules
    Patent number: 6949349
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: September 27, 2005
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Insulin-like growth factor agonist molecules
    Patent number: 6750321
    Abstract: Peptides are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist peptides are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: June 15, 2004
    Assignee: Genentech, Inc.
    Inventors: Yvonne Man-yee Chen, Ross G. Clark, Andrea G. Cochran, Henry B. Lowman, Iain C. A. F. Robinson, Nicolas J. Skelton
  • Insulin-like growth factor agonist molecules
    Patent number: 6743894
    Abstract: Peptides are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist peptides are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: June 1, 2004
    Assignee: Genentech, Inc.
    Inventors: Yvonne Man-yee Chen, Ross G. Clark, Andrea G. Cochran, Henry B. Lowman, Iain C. A. F Robinson, Nicholas J. Skelton
  • Insulin-like growth factor agonist molecules
    Patent number: 6716586
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: April 6, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Insulin-like growth factor agonist molecules
    Patent number: 6713451
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: March 30, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Insulin-like growth factor agonist molecules
    Patent number: 6693078
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: February 17, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Insulin-like growth factor agonist molecules
    Patent number: 6693079
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: February 17, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Insulin-like growth factor agonist molecules
    Patent number: 6689751
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: February 10, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Insulin-like growth factor agonist molecules
    Patent number: 6683053
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: January 27, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Insulin-like growth factor agonist molecules
    Patent number: 6680298
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: January 20, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Insulin-like growth factor agonist molecules
    Patent number: 6677305
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: January 13, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Method for treating cartilage disorders
    Publication number: 20030211992
    Abstract: The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor.
    Type: Application
    Filed: October 16, 2002
    Publication date: November 13, 2003
    Applicant: GENENTECH, INC.
    Inventors: Yvonne Man-Yee Chen, Ross G. Clark, Andrea G. Cochran, Yves Dubaquie, Paul J. Fielder, Ellen Filvaroff, Henry B. Lowman, Deborah L. Mortensen, Iain C.A.F. Robinson, Nicholas J. Skelton
  • Insulin-like growth factor agonist molecules
    Patent number: 6645775
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: November 11, 2003
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Insulin-like growth factor agonist molecules
    Patent number: 6635619
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which includes peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: October 21, 2003
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Insulin-like growth factor agonist molecules
    Patent number: 6632794
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: October 14, 2003
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson